How People Try to Beat Drug Testing and Defend Positive Results
|
By Kim Scott (AACC) Posted on 12 Jul 2022 |

Image: How People Try to Beat Drug Testing and Defend Positive Results (Photo courtesy of aacc.org)
Drug abuse is a critical problem throughout the world. While opioids are a significant public health concern, accounting for 2.88 million visits to emergency departments in the U.S. in 2016 and 2017, other drugs are also abused on a regular basis, including cocaine, amphetamines, and benzodiazepines.
In 1986, President Reagan directed federal agencies to achieve a drug-free work environment. Many private employers also employ drug testing to ensure their workplaces are safe. Approximately 20 million people are screened each year in the U.S. in workplace drug testing programs, said Amitava Dasgupta, PhD, professor of pathology and laboratory medicine at the University of Kansas Medical Center in Kansas City.
Dasgupta will discuss ways that people try to beat drug tests and strategies clinical laboratories can use to detect adulterated specimens during a roundtable session “How People Try to Beat Drug Testing and Defend Positive Results” at the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo on July 24-28 in Chicago.
About 2% of people undergoing drug testing attempt to “beat” the tests, Dasgupta said. Some people try to beat drug tests by ingesting detoxifying agents designed to flush out drugs and metabolites. Others add adulterants to their urine, such as common household chemicals –laundry bleach, table salt, toilet bowl cleaner, and vinegar. While these types of adulterants are fairly easy to identify, there are chemicals that can be purchased online that are more difficult to identify in urine. In addition, some individuals purchase synthetic urine online in an attempt to beat drug tests in settings where collection of a urine specimen is not supervised.
When attempts to beat drug tests fail and a test comes back positive, individuals sometimes blame the positive result on other issues, such as eating food with poppyseeds, inhaling second-hand marijuana smoke, or taking CBD products for pain.
Dasgupta will also discuss ways to debunk common defenses of positive drug tests. “This is a very important topic because we want to have a drug-free workplace, and lab medicine professionals who are involved in the field of toxicology testing play a big role in helping ensure a safe workplace,” he said. “It’s important to know ways in which people can try to beat drug tests so you know what to look out for.”
Among the topics that will be covered during this session:
“There are 14,000 sites on the internet that tell you how to beat a drug test, Dasgupta noted. “My goal is to make sure that toxicologists know how people try to beat tests so they can be prepared in advance.”
In 1986, President Reagan directed federal agencies to achieve a drug-free work environment. Many private employers also employ drug testing to ensure their workplaces are safe. Approximately 20 million people are screened each year in the U.S. in workplace drug testing programs, said Amitava Dasgupta, PhD, professor of pathology and laboratory medicine at the University of Kansas Medical Center in Kansas City.
Dasgupta will discuss ways that people try to beat drug tests and strategies clinical laboratories can use to detect adulterated specimens during a roundtable session “How People Try to Beat Drug Testing and Defend Positive Results” at the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo on July 24-28 in Chicago.
About 2% of people undergoing drug testing attempt to “beat” the tests, Dasgupta said. Some people try to beat drug tests by ingesting detoxifying agents designed to flush out drugs and metabolites. Others add adulterants to their urine, such as common household chemicals –laundry bleach, table salt, toilet bowl cleaner, and vinegar. While these types of adulterants are fairly easy to identify, there are chemicals that can be purchased online that are more difficult to identify in urine. In addition, some individuals purchase synthetic urine online in an attempt to beat drug tests in settings where collection of a urine specimen is not supervised.
When attempts to beat drug tests fail and a test comes back positive, individuals sometimes blame the positive result on other issues, such as eating food with poppyseeds, inhaling second-hand marijuana smoke, or taking CBD products for pain.
Dasgupta will also discuss ways to debunk common defenses of positive drug tests. “This is a very important topic because we want to have a drug-free workplace, and lab medicine professionals who are involved in the field of toxicology testing play a big role in helping ensure a safe workplace,” he said. “It’s important to know ways in which people can try to beat drug tests so you know what to look out for.”
Among the topics that will be covered during this session:
- What are common household chemicals that are often used to adulterate urine?
- What are commercially available products used to beat drug tests and how can you recognize when they are being used?
- How can you differentiate natural urine from synthetic urine?
- Protocols for detecting specific adulterants.
- What are common defenses for a positive drug test and how they can be debunked?
“There are 14,000 sites on the internet that tell you how to beat a drug test, Dasgupta noted. “My goal is to make sure that toxicologists know how people try to beat tests so they can be prepared in advance.”
Latest AACC 2022 News
- AACC 2022 Review: International Meetings Rebound After Suffering Long COVID Hiatus
- Faster Method Diagnoses Pediatric Urinary Tract Infections
- Tianlong Showcases Integrated PCR Lab Solutions at AACC 2022
- Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022
- Advanced Instruments Introduces New Automated Osmometer at AACC 2022
- Innovative Smartphone and AI-Based Tests Featured at AACC 2022
- New Tests Presented at AACC 2022 to Solve Challenges in Children's Healthcare
- 10-Minute Sepsis Risk Stratification Test Introduced at AACC 2022
- New System Combining DNA/RNA Extraction and Smart PCR Setup Launched at AACC 2022
- Novel Small Volume Blood Collection Device Launched at AACC 2022
- AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs
- Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022
- Nikon Instruments Displays Latest Clinical Pathology Products at AACC 2022
- Seegene Showcases Latest Molecular Testing Solutions at AACC 2022
- Werfen Introduces New Acute Care Diagnostic Products for CVOR at AACC 2022
- PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more





.jpg)


